NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company, is thrilled to announce a series of fall-themed product launches across its craft beer and beverage brands—Breckenridge Brewery, Montauk Brewing, Blue Point Brewing, Terrapin, and Shock Top. Tilray Beverages invites you to indulge in the season's festivities with an array of immersive experiences and latest releases crafted by their master brewers.

Tilray Achieves 13% Year-Over-Year Growth, Generating Record Q1 Net Revenue of $200 Million

TORONTO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company, announced the launch of new Charlotte's Web (TSX: CWEB) (OTCQX: CWBHF) CBD gummies in Canada. Designed specifically for daily CBD consumers, Charlotte’s Web CBD Rest Gummies and CBD Life Gummies offer an easy, delicious, and convenient way to incorporate CBD into your wellness routine.

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY and TSX: TLRY), through its newly formed Tilray Alternative Beverages business unit, unveils its portfolio of hemp-derived Delta-9 THC (HDD9) beverages to launch in key markets across the U.S., beginning in October 2024. Tilray’s lineup of HDD9 drinks include premium mocktails, seltzers and sparkling drinks made with high-quality hemp extracts and ingredients that provide consumers with a familiar, convenient, and delicious way to relax and unwind.

Le cannabis Redecan, certifié BPF-UE, est désormais disponible sur prescription médicale en Australie

LISBON, Portugal, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced a new scientific publication supported by Tilray Medical titled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS). The study examines the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM) under the guidance of healthcare providers.

LISBONNE, Portugal, 09 sept. 2024 (GLOBE NEWSWIRE) -- Tilray Medical, division de Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY) et leader mondial du cannabis thérapeutique, qui permet aux patients et aux professionnels de la santé de prendre ensemble des décisions de santé individualisées éclairées, a annoncé la publication d´une nouvelle étude scientifique à laquelle participe Tilray Medical, intitulée « Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS) » (« Traitement de la douleur et d’autres symptômes associés à la fibromyalgie : série de cas »). L’étude vise à évaluer l’impact des traitements à base de cannabinoïdes en conditions réelles sur les patients atteints de fibromyalgie (FM), sous la supervision de professionnels de santé.

Tilray’s Strategic Acquisition Will Strengthen its Craft Beer Leadership in the U.S. and Solidify Tilray Beverages as the #1 Craft Brewer in the Pacific Northwest and #1 in Georgia; Anchors Tilray in Key Markets, Texas and Michigan

Celebrate with live music, local vendors, raffles and prizes at Breckenridge Brewery’s First Pour Party

NEUMÜNSTER, Allemagne, 30 juill. 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), une société mondiale de premier plan opérant dans la recherche, la culture, la production et la distribution de cannabis médical, a annoncé aujourd’hui qu’Aphria RX GmbH (« Aphria RX ») a reçu une licence commerciale lui permettant de vendre et de distribuer une large gamme de produits à base de cannabis médical aux pharmacies, aux hôpitaux et aux grossistes en produits médicaux dans l’ensemble de l’Allemagne.